A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease

Yi-Bin Chen, MD, provides insight on treatment of steroid-refractory chronic GVHD with ruxolitinib.

EP. 1: Overview: A 42-Year-Old Woman With Moderate Steroid-Refractory Chronic GVHD

March 28th 2022

Yi-Bin Chen, MD, discusses the work-up, diagnosis, and treatment of a 42-year-old woman with moderate steroid-refractory chronic graft-versus-host disease (GVHD).

EP. 2: Risk Factors for Chronic GVHD and Steroid-Refractory Disease

March 28th 2022

A focused discussion on various risk factors for developing chronic GVHD and steroid-refractory disease.

EP. 3: Symptoms and Manifestations of Chronic GVHD

March 28th 2022

A comprehensive overview of the symptoms of and organs involved in chronic GVHD.

EP. 4: Early Diagnosis of Chronic GVHD and Tools for Severity Assessment

March 28th 2022

Insight on early diagnosis of chronic GVHD and the tools clinicians use to assess GVHD severity.

EP. 5: Treatment Options for Steroid-Refractory Chronic GVHD

March 28th 2022

Yi-Bin Chen, MD, discusses available treatment options for patients with steroid-refractory chronic GVHD.

EP. 6: Ruxolitinib Efficacy in Steroid-Refractory Chronic GVHD

March 28th 2022

A discussion of data from the REACH3 trial and real-world data on the efficacy of ruxolitinib in patients with steroid-refractory chronic GVHD.

EP. 7: Ruxolitinib Safety in Steroid-Refractory Chronic GVHD

March 28th 2022

A brief overview of safety and adverse events in the REACH3 trial of ruxolitinib in patients with steroid-refractory chronic GVHD.

EP. 8: Reflections on the Case and Risk Management for Chronic GVHD

March 28th 2022

Yi-Bin Chen, MD, reflects on the patient case and outlines strategies for educating and managing patients at risk of developing chronic GVHD.

EP. 9: Steroid-Refractory Chronic GVHD: Unmet Needs and Future Directions

March 28th 2022

Closing out his discussion, Yi-Bin Chen, MD, talks about unmet needs, ongoing clinical trials, emerging treatment options for patients with steroid-refractory chronic GVHD.